This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chien, P.-Y. Articles by Jameson, J. L. Search for Related Content PubMed PubMed Citation Articles by Chien, P.-Y. Articles by Jameson, J. L.

A Fusion Protein of the Estrogen Receptor (ER) and Nuclear Receptor Corepressor (NCoR) Strongly Inhibits Estrogen-Dependent Responses in Breast Cancer Cells

Division of Endocrinology, Metabolism, and Molecular Medicine Northwestern University Medical School Chicago, Illinois 60611

Nuclear receptor corepressor (NCoR) mediates repression (silencing) of basal gene transcription by nuclear receptors for thyroid hormone and retinoic acid. The goal of this study was to create novel estrogen receptor (ER) mutants by fusing transferable repressor domains from the N-terminal region of NCoR to a functional ER fragment. Three chimeric NCoR-ER proteins were created and shown to lack transcriptional activity. These fusion proteins silenced basal transcription of the ERE2-tk-Luc reporter gene and inhibited the activity of cotransfected wild-type ER (wtER), indicating that they possess dominant negative activity. One of the fusion proteins (CDE-RD1), containing the ER DNA-binding and ligand-binding domains linked to the NCoR repressor domain (RD1), was selected for detailed examination. Its hormone affinity, intracellular localization, and level of expression in transfected cells were similar to wtER, and it bound to the estrogen response element (ERE) DNA in gel shift assays. Glutathione-S-transferase pull-down assays showed that CDE-RD1 retains the ability to bind to steroid receptor coactivator-1. Introduction of a DNA-binding domain mutation into the CDE-RD1 fusion protein eliminated silencing and dominant negative activity. Thus, the RD1 repressor domain prevents transcriptional activation despite the apparent ability of CDE-RD1 to bind DNA, ligand, and coactivators. Transcriptional silencing was incompletely reversed by trichostatin A, suggesting a histone deacetylase-independent mechanism for repression. CDE-RD1 inhibited ER-mediated transcription in T47D and MDA-MB-231 breast cancer cells and repressed the growth of T47D cells when delivered to the cells by a retroviral vector. These ER-NCoR fusion proteins provide a novel means for inhibiting ER-mediated cellular responses, and analogous strategies could be used to create dominant negative mutants of other transcription factors.

This article has been cited by other articles:

				H. KASHIMA, A. HORIUCHI, J. UCHIKAWA, T. MIYAMOTO, A. SUZUKI, T. ASHIDA, I. KONISHI, and T. SHIOZAWA Up-regulation of Nuclear Receptor Corepressor (NCoR) in Progestin-induced Growth Suppression of Endometrial Hyperplasia and Carcinoma Anticancer Res, April 1, 2009; 29(4): 1023 - 1029. [Abstract] [Full Text] [PDF]

				C. D. Curtis, V. S. Likhite, I. X. McLeod, J. R. Yates, and A. M. Nardulli Interaction of the Tumor Metastasis Suppressor Nonmetastatic Protein 23 Homologue H1 and Estrogen Receptor {alpha} Alters Estrogen-Responsive Gene Expression Cancer Res., November 1, 2007; 67(21): 10600 - 10607. [Abstract] [Full Text] [PDF]

				T. K S Ku and D. L Crowe Coactivator-mediated estrogen response in human squamous cell carcinoma lines J. Endocrinol., April 1, 2007; 193(1): 147 - 155. [Abstract] [Full Text] [PDF]

				E. J. Lee and J L. Jameson Gene therapy of pituitary diseases J. Endocrinol., June 1, 2005; 185(3): 353 - 362. [Abstract] [Full Text] [PDF]

				T. Shiozawa, H.-C. Shih, T. Miyamoto, Y.-Z. Feng, J. Uchikawa, K. Itoh, and I. Konishi Cyclic Changes in the Expression of Steroid Receptor Coactivators and Corepressors in the Normal Human Endometrium J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 871 - 878. [Abstract] [Full Text] [PDF]

				E. Demirpence, A. Semlali, J. Oliva, P. Balaguer, E. Badia, M.-J. Duchesne, J.-C. Nicolas, and M. Pons An Estrogen-responsive Element-targeted Histone Deacetylase Enzyme Has an Antiestrogen Activity That Differs from That of Hydroxytamoxifen Cancer Res., November 15, 2002; 62(22): 6519 - 6528. [Abstract] [Full Text] [PDF]

				E. J. Lee, W. R. Duan, M. Jakacka, B. D. Gehm, and J. L. Jameson Dominant Negative ER Induces Apoptosis in GH4 Pituitary Lactotrope Cells and Inhibits Tumor Growth in Nude Mice Endocrinology, September 1, 2001; 142(9): 3756 - 3763. [Abstract] [Full Text] [PDF]

				T. L. Woodward, H. Lu, and S. Z. Haslam Laminin Inhibits Estrogen Action in Human Breast Cancer Cells Endocrinology, August 1, 2000; 141(8): 2814 - 2821. [Abstract] [Full Text] [PDF]

				G. de Haan, S. Chusacultanachai, C. Mao, B. S. Katzenellenbogen, and D. J. Shapiro Estrogen Receptor-KRAB Chimeras Are Potent Ligand-dependent Repressors of Estrogen-regulated Gene Expression J. Biol. Chem., April 28, 2000; 275(18): 13493 - 13501. [Abstract] [Full Text] [PDF]

				M. Jakacka, M. Ito, J. Weiss, P.-Y. Chien, B. D. Gehm, and J. L. Jameson Estrogen Receptor Binding to DNA Is Not Required for Its Activity through the Nonclassical AP1 Pathway J. Biol. Chem., April 20, 2001; 276(17): 13615 - 13621. [Abstract] [Full Text] [PDF]

				Q. Wang, J. Lu, and E. L. Yong Ligand- and Coactivator-mediated Transactivation Function (AF2) of the Androgen Receptor Ligand-binding Domain Is Inhibited by the Cognate Hinge Region J. Biol. Chem., March 2, 2001; 276(10): 7493 - 7499. [Abstract] [Full Text] [PDF]

				R. A. Campbell, P. Bhat-Nakshatri, N. M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor alpha . A NEW MODEL FOR ANTI-ESTROGEN RESISTANCE J. Biol. Chem., March 23, 2001; 276(13): 9817 - 9824. [Abstract] [Full Text] [PDF]